Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. Ulmert D, et al. Among authors: fox jj. Eur Urol. 2012 Jul;62(1):78-84. doi: 10.1016/j.eururo.2012.01.037. Epub 2012 Jan 27. Eur Urol. 2012. PMID: 22306323 Free PMC article.
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
Meirelles GS, Schöder H, Ravizzini GC, Gönen M, Fox JJ, Humm J, Morris MJ, Scher HI, Larson SM. Meirelles GS, et al. Among authors: fox jj. Clin Cancer Res. 2010 Dec 15;16(24):6093-9. doi: 10.1158/1078-0432.CCR-10-1357. Epub 2010 Oct 25. Clin Cancer Res. 2010. PMID: 20975102 Free PMC article. Clinical Trial.
Molecular imaging of prostate cancer.
Fox JJ, Schöder H, Larson SM. Fox JJ, et al. Curr Opin Urol. 2012 Jul;22(4):320-7. doi: 10.1097/MOU.0b013e32835483d5. Curr Opin Urol. 2012. PMID: 22617062 Free PMC article. Review.
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI. Rathkopf DE, et al. Among authors: fox jj. J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3. J Clin Oncol. 2013. PMID: 24002508 Free PMC article. Clinical Trial.
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H. Vargas HA, et al. Among authors: fox jj. Radiology. 2014 Apr;271(1):220-9. doi: 10.1148/radiol.13130625. Epub 2013 Nov 18. Radiology. 2014. PMID: 24475817 Free PMC article.
Response.
Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H. Vargas HA, et al. Among authors: fox jj. Radiology. 2015 Feb;274(2):625. Radiology. 2015. PMID: 25785291 No abstract available.
215 results